Smith & Nephew PLC has announced its third-quarter results for 2026, highlighting a revenue growth of 3.4% compared to the same period last year. This growth is attributed to strong performances in its Sports Medicine and Advanced Wound Management divisions. However, the company has revised its full-year guidance due to slower-than-expected growth in its Orthopaedics segment. This update is significant not only for Smith & Nephew but also reflects ongoing challenges within the orthopedic, prosthetic, and surgical appliances industry.
Background
Smith & Nephew PLC, a leading player in the orthopedic, prosthetic, and surgical appliances and supplies sector, operates under the ticker symbols SNN on the NYSE and SNNUF on the OTC. The company is headquartered in Watford, Hertfordshire, England, and is classified as a large accelerated filer. Recent filings include a series of 6-K reports and an S-8 registration statement, with the latest filing dated November 4, 2026.
What the Filing Says
In its latest filing, Smith & Nephew reported a revenue of $1,551 million for Q3 2026, up from $1,501 million in Q3 2025. The company noted, “We saw continued momentum in Sports Medicine & ENT, including double-digit growth in Joint Repair, and improved performance in Advanced Wound Management.” Despite this growth, the company acknowledged challenges in the Orthopaedics segment, particularly in the U.S. market.
Impact
The revised guidance and performance update may affect various stakeholders, including shareholders, employees, and healthcare providers relying on Smith & Nephew’s products. The company’s focus on enhancing operational efficiency and exploring strategic options for its Orthopaedics business indicates a proactive approach to addressing market challenges.
What's Next
The filing does not specify what happens next regarding the company's strategic options for its Orthopaedics business, but it confirms that discussions with Johnson & Johnson have ended. Smith & Nephew continues to explore all avenues to enhance shareholder value and improve business performance.
Read Next
Seaport Therapeutics Director Acquires 5,000 Shares
Cynthia Pussinen reports stock option grant as CEO of Estrella
ATS Corp Reports Q2 Results, Emphasizing Growth Strategies
Worksport Signs Term Sheet to Acquire Truck Bed Accessory Business
Itaú Unibanco reports on activities and performance update
Aurora Cannabis to Merge with Organigram in Major Deal









